| Literature DB >> 32052231 |
Babak Banan1, Jacob A Beckstead2, Lauren E Dunavant2, Yoojin Sohn3, Jamie M Adcock1, Sachiyo Nomura4, Naji Abumrad1, James R Goldenring1,3,5, Barbara Fingleton6,7.
Abstract
Current laboratory models of lymphatic metastasis generally require either genetically modified animals or are technically challenging. Herein, we have developed a robust protocol for the induction of intralymphatic metastasis in wild-type mice with reproducible outcomes. To determine an optimal injection quantity and timeline for tumorigenesis, C57Bl/6 mice were injected directly into the mesenteric lymph duct (MLD) with varying numbers of syngeneic murine colon cancer cells (MC38) or gastric cancer cells (YTN16) expressing GFP/luciferase and monitored over 2-4 weeks. Tumor growth was tracked via whole-animal in vivo bioluminescence imaging (IVIS). Our data indicate that the injection of tumor cells into the MLD is a viable model for lymphatic metastasis as necropsies revealed large tumor burdens and metastasis in regional lymph nodes. This protocol enables a closer study of the role of lymphatics in cancer metastasis and opens a window for the development of novel approaches for treatment of metastatic diseases.Entities:
Keywords: Colon cancer; Gastric cancer; Intralymphatic; Luciferase; Mesenteric lymph duct
Mesh:
Substances:
Year: 2020 PMID: 32052231 PMCID: PMC7979265 DOI: 10.1007/s10585-020-10025-3
Source DB: PubMed Journal: Clin Exp Metastasis ISSN: 0262-0898 Impact factor: 5.150